EXV-802 / Exciva - LARVOL DELTA

SERENADA: Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia (clinicaltrials.gov) - P2/3 | N=300 | Recruiting | Sponsor: Exciva GmbH | Not yet recruiting ➔ Recruiting | Trial completion date: Jun 2029 ➔ Feb 2029

Enrollment open • Trial completion date • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia